Participated · Series A · Nov 2022

Sensorium Therapeutics develops brain and mental health treatments derived from natural products and driven by mechanistic neuroscience. Its proprietary SensAI platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience. SensAI has produced three differentiated programs in under three years, led by SNTX-2643, a first-in-class precision serotonin modulator for anxiety. The company recently received FDA clearance of an IND for SNTX-2643, enabling first-in-human dosing beginning in Q3 2025. Sensorium describes SNTX-2643 as re-engineered from a natural product to enable rapid onset, reduce off-target side effects, and avoid sedation versus benzodiazepine-like drugs. Sensorium has built an IP estate extending into the 2040s and has made executive leadership changes concurrent with its clinical advancement. Sensorium Therapeutics is a Boston-based biotechnology company developing nature-inspired psychoactive medicines for mental health. The company leverages medicinal chemistry, neuroscience, and machine learning to discover and optimize compounds. Its initial asset is SENS-01 and it operates the Biodynamic Discovery Platform (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. Sensorium closed a $30 million Series A financing to advance SENS-01 and further develop the BDP. The company aims to use the proceeds to move those programs forward.

Participated · Seed · Feb 2022

Fluence is an expertise-driven educational platform that provides professional certification and training in psychedelic therapy and integration. Founded in 2019 and based in NYC, the company works directly with licensed healthcare professionals and graduate students to advance clinical skills and evidence-based psychedelic care. Over the past two years it has trained nearly 1,000 practitioners and has partnerships with drug developers including Beckley Psytech, Tryp Therapeutics, and Clairvoyant Therapeutics to develop therapy manuals and custom training for clinical trial therapists. Fluence plans to expand its course and certificate offerings and bolster development of training software and its e-learning platform. The company is also developing a psilocybin-assisted therapy program to meet Oregon Health Authority requirements ahead of Measure 109 implementation. Leadership includes founders Dr. Ingmar Gorman and Dr. Elizabeth Nielson and COO Michael Kuntz.

Led · Seed · Jul 2021

Psilera is a biopharmaceutical company developing novel neuroplastogens and psychedelic-derived therapies, headquartered in Tampa, Fla. Its lead compound, PSIL-006, is described as a first-in-class neuroplastogen designed to capture therapeutic benefits of traditional psychedelics while minimizing hallucinogenic and cardiovascular effects. The company plans to advance PSIL-006 into first-in-human trials in 2027 and is using its recent financing to support that transition to clinical-stage development. Psilera has secured an NIH award of up to $2 million for IND-enabling studies in alcohol use disorder and executed a strategic licensing agreement with atai Life Sciences (now AtaiBeckley) for a DMT patent portfolio. Recent corporate developments include the appointment of Magali Haas, MD/PhD, as Chief Medical Officer as Psilera scales operations toward clinical milestones.